Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Artios Pharma Ltd.

www.artiospharma.com

Latest From Artios Pharma Ltd.

Finance Watch: Investments In Regenerative Therapies Surged In The Second Quarter

Global financings for cell and gene therapy and tissue engineering companies more than doubled in the second quarter; financings for the sector rose 79% in the first half of 2018. Also, Samumed leads recent venture funding deals with a $438m round.

Financing Regenerative Medicine

Artios Pharma Hooks Novartis & Pfizer In Over-Subscribed £65M Series B Round

With DNA damage repair pathways attracting a lot of attention as potential targets against various cancers, three-year old Artios Pharma has raised £65 million in an over-subscribed Series B round to fund the clinical development of its pipeline through to 2023.
Financing Cancer

Artios Banks On DNA Repair To Challenge IO Space

With a better understanding of how DNA damage repair (DDR) pathways operate in cancer cells, UK biotech Artios Pharma, in partnership with Cancer Research UK, is looking to develop drug candidates that can selectively kill tumor cells. Speaking at the Biotech Showcase 2018, Artios CEO Niall Martin told Scrip how the company is advancing its lead programs towards the clinic and is seeking series B venture capital to demonstrate proof of concept for the lead programs.

 

Cancer StartUps and SMEs

A Different Approach To Corporate Venture: An Interview With AbbVie Ventures' Scott Brun

AbbVie Ventures is young, but the group was set up with specific goals: to invest specifically in tune with AbbVie's therapeutic focus areas and not to focus purely on return on investment.

Business Strategies Financing
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Artios Pharma Ltd.
  • Senior Management
  • Niall Martin, PhD, CEO
    Andrew Muncey, CFO
    Graeme Smith, PhD, CSO
    Nick Staples, PhD, CBO
    Peter Harris, CMO
  • Contact Info
  • Artios Pharma Ltd.
    Phone: 1223 804180
    c/o The Babraham Institute
    Meditrina B260
    Babraham, CB22 3AT
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register